Quick Listen: Scrip’s Five Must-Know Things

In this week's episode: low-cost Wegovy an alternative for US self-payers; Bayer rolls up sleeves for turnaround; taking the pulse of NewCo creation; the outlook for Alzheimer’s; and India’s rare disease landscape.

Scrip Five Must Know Things
weekly audio roundup of selected content from Scrip's global team

Join us for an audio catch-up on the major events in the global biopharma industry over the past business week, as reported by Scrip‘s global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 7 March 2025, including: low-cost Wegovy an alternative for US self-payers; Bayer rolls up sleeves for turnaround; taking the pulse of NewCo creation; the outlook for Alzheimer’s; and India’s rare disease landscape.

This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

Novo’s Low-Cost Wegovy Offers Alternative To Compounders For Self-Pay Crowd

Bayer Rolls Up Its Sleeves But Turnaround Will Take Time

The Biopharma A List: Taking The Pulse of Newco Creation In 2024

ADDF’s Harris On Alzheimer’s Outlook And Investment

India Landscape For Rare Disease Therapies: Hope, Despair And Funding Hoops

More from Scrip's Five Must-Know Things

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: top drugs in the first quarter; deal trends at bio; Novo and Lilly’s obesity segmentation plans; Chinese firms at ADA; and five drugs that surpassed sales expectations.

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: US policies in spotlight at BIO; Lilly’s Verve acquisition; UroGen’s bladder cancer approval; Ireland’s biopharma talent; and Korea proposes new AI R&D project.

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: breaking down big pharma’s executive pay; US vaccine panel upheaval; Merck’s RSV approval; MFN and Japan; and the future of Pfizer and Arvinas’s partnership.

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: Sanofi’s Blueprint buy; AstraZeneca’s breast cancer resistance results at ASCO; BMS and BioNTech’s big bispecific deal; Kymera’s Dupixent in a pill; and Degron’s CEO on pipeline and strategy.

More from Business

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By 

Multi-blockbuster falls short in a giant cell arteritis study.

In Brief: BioVersys And Shionogi Align In Non-Tuberculous Mycobacteria R&D

 
• By 

Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By 

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.